Appreciating China

Winds of change favour China’s advanced tech companies

China has a long history at the forefront of innovation, and government policy is ensuring it continues that tradition to drive the next stage of the country’s ongoing economic growth story.

Key takeaways:

  • China has ambitious economic growth targets, and advances in tech and innovation will be integral to achieving this vision
  • Government policy is fostering innovation in China, with recent policy changes relating to the tech sector helping industrial tech players to outperform consumer tech
  • Companies that embrace these changes – in available technology and government policy – will be well positioned to benefit

China’s most recent five-year plan, published in 2020, featured the word “innovation” 165 times while “digital” appeared 81 times. By contrast, “the Communist Party” was mentioned only 54 times. The importance China’s government is placing on its intensifying quest to become a tech superpower is clear, as it looks to double its GDP by 2035.

China’s recent growth story has been synonymous with consumer tech – both platforms and hardware – but the country is sharpening its focus on high-tech manufacturing, and embarking on a new wave of innovation intended to secure its position as the global leader in industrial tech. Succeeding in this goal will be key to China achieving self-sufficiency in those areas of the economy that it considers most strategically important, such as building the tech infrastructure needed to underpin the country’s targeted growth.

Notably the government has adopted a policy of channelling investment and resources into industrial tech over consumer tech. Equity markets foresaw this change in tech policy as long ago as 2019, when the semiconductor index started to outperform the internet index. That was two years before a high-profile crackdown on consumer tech began in 2021, which saw tighter government monitoring and stricter regulatory enforcement in the sector, impacting several big-name Chinese tech stocks.

A shift in government focus on tech

These policy shifts can tell us a lot about government plans for the future of tech in China. As a result, some domestic Chinese stocks could appeal to investors looking to benefit from China’s ongoing emergence as a distinct tech superpower.

Evidence of China’s new wave of innovation abounds. It is already the world’s largest market for electric vehicles (EVs), accounting for about 40% of global sales; it is the world leader in renewables, with more than 70% of global output across the solar production chain; it has more than 1,000 new drugs currently in development; and is the world’s largest market for industrial robots.

Additionally, China accounts for the highest number of patent and trademark applications globally; in 2020, the country accounted for 45.7% of all patent filings and 54.3% of trademarks.1 As Exhibit 1 shows, North America still leads in terms of research and development spending, but China is closing the gap.

Exhibit 1: Global R&D expenditure (USD bn)
Exhibit 1: Global R&D expenditure (USD bn)

Source: OECD data, Allianz Global Investors, as of 2020

Policy supporting new tech

Those companies at the forefront of harnessing new technologies are benefiting from policy and economic tailwinds, which are accelerating their profit growth. We believe that opportunities will exist for investors in areas such as industrial automation, green tech, healthcare, semiconductors, and smart transportation.

Robot density is often used as a yardstick of a country’s technological development. With an ageing population and increasing labour costs, Chinese companies are embracing industrial automation and installing robots at a rate that has seen the country quickly rise to rank in the top 10 countries globally in terms of robot density. The adoption of robotics is likely still at an early stage and there remains further room for growth.

Semiconductors are probably even more important for the country’s future ambitions. By value, China imports more semiconductors than it does oil. The chips are the key commodity for various aspects of manufacturing tech. Just consider EVs: as Exhibit 2 shows, semiconductors are needed for functions including motor control, cameras, human-machine interaction, high-performance processors, display systems and many other features. As demand for the technology underpinned by semiconductors rises, so demand for the semiconductors themselves will likely rise in line.

Exhibit 2: Semiconductor demand to rise with technological advancement (eg, smart transportation)
Exhibit 2: Semiconductor demand to rise with technological advancement (eg, smart transportation)

Source: Allianz Global Investors

Pioneering medicine

Another area of innovation that is growing rapidly – driven by the burgeoning needs of a population which is growing older and more affluent, but less healthy– is healthcare. By 2060, we estimate that China’s population will include about 400 million over-65s – almost a third of the population. About half of that number are predicted to suffer from cancer or cardiovascular or neurological diseases. At the same time, rates of diabetes and obesity are surging among younger people.

To treat these illnesses, innovation in drug development and medical devices is booming. As Exhibit 3 illustrates, there are around 1,500 drugs in clinical trials, up from about 300 as recently as 2016.

Healthcare innovation will likely drive further opportunities for investors as China seeks to build on its long history of pioneering medicine. Currently the market capitalisation of the five biggest Chinese healthcare companies, equates to only about a quarter of the five largest EU healthcare firms, and just 15% of the five largest US firms’ market cap. We anticipate significant room for further growth in the next 10 to 20 years.

Exhibit 3: Number of Chinese clinical trials for “innovative” drugs
Exhibit 3: Number of Chinese clinical trials for “innovative” drugs

Source: PharmaGO database as at May 2022. The information above is provided for illustrative purposes only, it should not be considered a recommendation to purchase or sell any particular security or strategy or an investment advice. Past performance, or any prediction, projection or forecast, is not indicative of future performance.

Industrial tech and healthcare driving China’s growth

While sectors like domestic consumption and real estate led China’s growth in the past decade, in the 2020s the baton has been handed to advanced technology, most notably industrial tech and healthcare. The importance of these sectors to the broader Chinese economy should mean that the government continues to foster a supportive environment for companies operating in these areas.

These sectors have already seen significant expansion, as Exhibit 4 shows. Those companies harnessing innovation most successfully should yield still greater opportunity in the future.

Exhibit 4: Number of stocks per sector in MSCI China and MSCI China A Onshore Index combined
Exhibit 4: Number of stocks per sector in MSCI China and MSCI China A Onshore Index combined

Source: Bloomberg as at 31 March 2022. The information above is provided for illustrative purposes only, it should not be considered a recommendation to purchase or sell at any particular security or strategy or an investment advice.

1) WIPO Statistics Database, February 2022

  • Disclaimer
    Investing involves risk. The value of an investment and the income from it will fluctuate and investors may not get back the principal invested. Past performance is not indicative of future performance. This is a marketing communication. It is for informational purposes only. This document does not constitute investment advice or a recommendation to buy, sell or hold any security and shall not be deemed an offer to sell or a solicitation of an offer to buy any security.

    The views and opinions expressed herein, which are subject to change without notice, are those of the issuer or its affiliated companies at the time of publication. Certain data used are derived from various sources believed to be reliable, but the accuracy or completeness of the data is not guaranteed and no liability is assumed for any direct or consequential losses arising from their use. The duplication, publication, extraction or transmission of the contents, irrespective of the form, is not permitted.

    This material has not been reviewed by any regulatory authorities. In mainland China, it is for Qualified Domestic Institutional Investors scheme pursuant to applicable rules and regulations and is for information purpose only. This document does not constitute a public offer by virtue of Act Number 26.831 of the Argentine Republic and General Resolution No. 622/2013 of the NSC. This communication’s sole purpose is to inform and does not under any circumstance constitute promotion or publicity of Allianz Global Investors products and/or services in Colombia or to Colombian residents pursuant to part 4 of Decree 2555 of 2010. This communication does not in any way aim to directly or indirectly initiate the purchase of a product or the provision of a service offered by Allianz Global Investors. Via reception of his document, each resident in Colombia acknowledges and accepts to have contacted Allianz Global Investors via their own initiative and that the communication under no circumstances does not arise from any promotional or marketing activities carried out by Allianz Global Investors. Colombian residents accept that accessing any type of social network page of Allianz Global Investors is done under their own responsibility and initiative and are aware that they may access specific information on the products and services of Allianz Global Investors. This communication is strictly private and confidential and may not be reproduced. This communication does not constitute a public offer of securities in Colombia pursuant to the public offer regulation set forth in Decree 2555 of 2010. This communication and the information provided herein should not be considered a solicitation or an offer by Allianz Global Investors or its affiliates to provide any financial products in Brazil, Panama, Peru, and Uruguay. In Australia, this material is presented by Allianz Global Investors Asia Pacific Limited (“AllianzGI AP”) and is intended for the use of investment consultants and other institutional/professional investors only, and is not directed to the public or individual retail investors. AllianzGI AP is not licensed to provide financial services to retail clients in Australia. AllianzGI AP is exempt from the requirement to hold an Australian Foreign Financial Service License under the Corporations Act 2001 (Cth) pursuant to ASIC Class Order (CO 03/1103) with respect to the provision of financial services to wholesale clients only. AllianzGI AP is licensed and regulated by Hong Kong Securities and Futures Commission under Hong Kong laws, which differ from Australian laws.

    This document is being distributed by the following Allianz Global Investors companies: Allianz Global Investors U.S. LLC, an investment adviser registered with the U.S. Securities and Exchange Commission; Allianz Global Investors Distributors LLC, distributor registered with FINRA, is affiliated with Allianz Global Investors U.S. LLC; Allianz Global Investors GmbH, an investment company in Germany, authorized by the German Bundesanstalt für Finanzdienstleistungsaufsicht (BaFin); Allianz Global Investors (Schweiz) AG; in HK, by Allianz Global Investors Asia Pacific Ltd., licensed by the Hong Kong Securities and Futures Commission; ; in Singapore, by Allianz Global Investors Singapore Ltd., regulated by the Monetary Authority of Singapore [Company Registration No. 199907169Z]; in Japan, by Allianz Global Investors Japan Co., Ltd., registered in Japan as a Financial Instruments Business Operator [Registered No. The Director of Kanto Local Finance Bureau (Financial Instruments Business Operator), No. 424], Member of Japan Investment Advisers Association, the Investment Trust Association, Japan and Type II Financial Instruments Firms Association; in Taiwan, by Allianz Global Investors Taiwan Ltd., licensed by Financial Supervisory Commission in Taiwan; and in Indonesia, by PT. Allianz Global Investors Asset Management Indonesia licensed by Indonesia Financial Services Authority (OJK).

    2402302

Recent insights

We expect biodiversity to be a major theme for investors in 2023, after the recent COP 27 formally acknowledged the link between the climate and biodiversity crises – as underscored by severe weather events this year. We hope that the upcoming COP 15 – a conference dedicated to biodiversity – will agree a global biodiversity framework for the coming decade that will live up to high expectations.

Discover more

Watch our November update on global capital markets with Gregor Hirt, CIO of Multi Asset at Allianz Global Investors. Learn more about Gregor's view on the market developments of recent months, the capital market outlook for the coming months, and how this affects positioning in the multi-asset context.

Discover more

The traditional approach to increasing yields in agriculture relies on seeking incremental gains via refining existing processes and making more efficient use of capital; for instance, by way of improving fertilizers and pest control, or using bigger and better machinery.

Discover more